Hypercalcaemia.

tivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995;80:153–9. 12 Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75–81. 13 Fowelin J, Attrall S, Lager I, Bengtsson BA. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993;42:1443–7. 14 Rosen T, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U et al. The influence of GH deficiency, GH replacement therapy and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001;16:398–405. 15 Drake WM, Howell SJ, Monson JP, Shalet SM. Optimising GH therapy in adults and children. Review. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database. Endocr Rev 2001;22:425–50. 16 Monson JP, Abs R, Bengtsson BA, Bennmarker H, et al. Growth hormone deficiency and replacement in elderly hypopituitary adults. Clin Endocrinol (Oxf) 2000;53:281–9. 17 Hernberg-Stahl E, Luger A, Abs R, Bengtsson BA et al. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab 2001;86:5277–81.